The International Triathlon Union (ITU) has opened bidding for the 2018 ITU World Triathlon Series, as well as the 2018 ITU World Cups. Interested cities must send their applications before 20 June 2017.“The World Triathlon Series is the pinnacle of our sport, and brings the world’s best triathletes to a city, offering international exposure to a global audience, and a live thrilling atmosphere of the elite level racing,” said ITU President and IOC Member Marisol Casado. “Triathlon as a sport continues to grow around the globe, attracting thousands of triathletes and spectators to our events, and we offer the cities the possibility of hosting one of our exciting events, an ideal way to promote sport, and the city gaining international attention.”The ITU World Triathlon Series (WTS) is positioned as ‘the premier triathlon series in the world’ and features the world’s best Sprint and Olympic distance triathletes racing head-to-head in up to 10 races around the globe, including the Grand Final. In addition to competing for the title of world champion, athletes vie for a total prize purse of over US$2-million, ‘the greatest cumulative prize purse in triathlon’.The World Triathlon Series is comprised of Olympic distance events (1.5km swim, 40km bike and a 10km run), sprint distance events (750m swim, 20km bike and a 5km run), two days’ semi-final/final formats, and Mixed Relay events, one of which will also be the ITU Triathlon Mixed Relay World Championship. The ITU World Cup events will be also staged on Olympic distance, Sprint distance and two days’ semi-final/final formats, as part of ITU’s goal in creating the event pathway for cities interested in hosting ITU events.ITU adds that hosting a WTS event offers cities the opportunity to showcase themselves to millions of people via a live international television broadcast in addition to attracting thousands of international guests and race participants. Annual on-site spectators for the series are upwards of 1 million. In additionm an hour long magazine show is produced from each event, as well as live internet coverage, social media exposure and worldwide news distribution.The ITU Triathlon World Cup competitions are the second tier events for ITU, intended to provide a solid and professional base for triathletes pursuing entry to the World Triathlon Series and qualification for the Olympics Games and other Major Games. These events are also aligned with ITU Development programmes, carry a prize purse, and have significant media, television and internet coverage, making it attractive for tourist locations and major cities.Cities hosting World Cups can expect to attract an audience of millions of people around the world, including international TV distribution alongside the WTS magazine show package for a customized 16 to 24-minutes highlight show, as well as international news distribution, internet TV coverage and international print media coverage.Cities interested in hosting a race on the 2018 World Triathlon Series calendar or 2018 ITU World Cup event calendar must submit their bid to ITU by 20 June 2017, where successful cities will be notified on 10 September 2017.www.triathlon.org Related
Share LinkedIn Share on Twitter Pinterest For more than five years, urine and cerebral-spinal fluid samples from patients with Parkinson’s disease have been locked in freezers in the NINDS National Repository, stored with the expectation they might someday help unravel the still-hidden course of this slow-acting neurodegenerative disease.Now, research by Andrew West, Ph.D., and colleagues at the University of Alabama at Birmingham has revealed that the tubes hold a brand-new type of biomarker — a phosphorylated protein that correlates with the presence and severity of Parkinson’s disease. West and colleagues, with support from the National Institutes of Health, the Michael J. Fox Foundation for Parkinson’s Disease Research and the Parkinson’s Disease Foundation, are digging deeper into these biobanked samples, to validate the biomarker as a possible guide for future clinical treatments and a monitor of the efficacy of potential new Parkinson’s drugs in real time during treatment.“Nobody thought we’d be able to measure the activity of this huge protein called LRRK2 (pronounced lark two) in biofluids since it is usually found inside neurons in the brain,” said West, co-director of the Center for Neurodegeneration and Experimental Therapeutics, and the John A. and Ruth R. Jurenko Professor of Neurology at UAB. “New biochemical markers like the one we’ve discovered together with new neuroimaging approaches are going to be the key to successfully stopping Parkinson’s disease in its tracks. I think the days of blindly testing new therapies for complex diseases like Parkinson’s without having active feedback both for ‘on-target’ drug effects and for effectiveness in patients are thankfully coming to an end.” Share on Facebook Email A biomarker helps physicians predict, diagnose or monitor disease, because the biomarker corresponds to the presence or risk of disease, and its levels may change as the disease progresses. Validated biomarkers can aid both preclinical trial work in the laboratory and future clinical trials of drugs to treat Parkinson’s. West and others are paving the way for an inhibitor drug that prevented neuroinflammation and neurodegeneration in an animal model of the disease, as reported last year by West and colleagues.The new biomarker findings were published in Neurology in March and Movement Disorders in June. The biomarker, LRRK2, has been shown to play a role in hereditary Parkinson’s, and the most common of these mutations — called G2019S — causes the LRRK2 kinase to add too many phosphates to itself and other proteins. Why this leads to Parkinson’s disease is not yet clear.The key to West’s biomarker approach was the recognition that LRRK2 can be purified from a new type of vesicle called exosomes found in all human biofluids, like urine and saliva. Cells in the body continually release exosomes that contain a mixture of proteins, RNA and DNA derived from different kinds of cells. West and colleagues were able to purify exosomes from 3- or 4-ounce urine samples donated by patients, and then measure phosphorylated LRRK2 in those exosomes.The findingsIn the Neurology study, they found that elevated phosphorylated LRRK2 predicted the risk for onset of Parkinson’s disease for people carrying a mutation in LRRK2, which is about 2-3 percent of all Parkinson’s disease patients. These findings were first tested with a preliminary, 14-person cohort of urine samples from the Columbia University Movement Disorders Center. That was followed by a larger replication study of 72 biobanked urine samples from the Michael J. Fox Foundation LRRK2 Cohort Consortium. All samples were provided to UAB in a blinded fashion to ensure the approach was rigorous.The follow-up Movement Disorders paper — the first study of its type — expanded the scope to people without LRRK2 mutations, which is most Parkinson’s disease patients. Using 158 urine samples from Parkinson’s disease patients and healthy controls enrolled in the UAB Movement Disorder Clinic as part of the NIH Parkinson’s Disease Biomarker Program, West and colleagues found that approximately 20 percent of people without LRRK2 mutations but with Parkinson’s disease also showed highly elevated phosphorylated LRRK2 similar to people with LRRK2 mutations, and this was not present in healthy controls. The study speculates that people with elevated phosphorylated LRRK2 may be particularly good candidates for future drugs that reduce phosphorylated LRRK2.Next stepsQuestions remain for this evidence of biochemical changes in LRRK2 in idiopathic Parkinson’s disease. One is finding out where the urinary exosomes come from. Given a suspected role for inflammation in Parkinson’s disease, it is interesting that LRRK2 is highly expressed in cells of the innate immune system. A possible explanation for the phosphorylated LRRK2 in patients with more severe disease may be an increased inflammation in those patients who have aggressive progression of disease.In May, West was awarded a new U01 collaborative grant from the National Institute of Neurological Disorders and Stroke to further explore urinary exosomes and extend the observations to cerebral-spinal fluid as a marker for disease prediction and prognosis.
LSI President Brett Tennar says, “Steve’s success in developing operational strategies that improves the bottom line, builds teamwork, reduces waste and ensures quality product development and distribution checks many of the boxes of what we were looking for in a COO. This, coupled with his career in the Air Force working with highly technical systems and his in-depth understanding of Lean Six Sigma and Business Process Management sealed our offer. As our tagline states, our products are Powered by Science. This data driven approach is one reason why our company has grown exponentially as we employ the most advanced technology to product development. I am confident that Steve is the right person to drive operational strategy for our diverse and growing brands.” Advertisement With more than 20 years of experience across multiple industries and functional areas, deMoulpied has particular expertise in organizations with complex technical products. Combined, his prior positions have required a spectrum of skills in corporate strategy, operations improvement, product quality, and revenue cycle management. He has an impressive history of utilizing data driven problem solving (Lean Six Sigma) and project management (PMP and CSM) to achieve strategic goals surrounding customer satisfaction, operational efficiency and improved profit. DeMoulpied comes to LSI from the Private Client Services practice of Ernst & Young where he managed strategy & operations improvement engagements for privately held client businesses. Some of his prior roles include VP of strategic development, director of strategic initiatives, and Lean Six Sigma Master Black Belt at OptumHealth, UnitedHealth Group’s health services business, as well as Lean Six Sigma Black Belt at General Electric, where he applied operations improvement principles to customer service, supply chain and product development. A successful entrepreneur, deMoulpied is also the founder of PrestoFresh, a Cleveland-based e-commerce food/grocery business. FORT LAUDERDALE, FL — Michael Bland has joined Forecast Products Corp. as vice president of sales. An industry veteran with more than 30 years of aftermarket experience, Bland will head the sales effort at Forecast, focusing on aggressively growing the company’s traditional business both with its Original Engine Management (OEM) brand and in the private-label channels. Most recently, Bland headed the aftermarket initiative at Prestolite Wire for the past eight years. AdvertisementClick Here to Read MoreAdvertisementForecast has been an industry leader in engine management, ignition and filters for more than 25 years. With more than 5,000 SKUs, its on-line catalog (oemautoparts.net) covers more than 95 percent of the most popular import and domestic applications. Working with Vertical Development, Forecast is able to tailor and customize specific catalog needs for any customer, as well as map to all electronic platforms. _______________________________________ Click here to view the rest of today’s headlines.,Lubrication Specialties Inc. (LSI), manufacturer of Hot Shot’s Secret brand of performance additives and oils, recently announced the expansion of senior leadership. Steve deMoulpied joins LSI as the company’s chief operating officer (COO). AdvertisementClick Here to Read MoreAdvertisement DeMoulpied has a Bachelor of Science degree in Engineering Management from the United States Air Force Academy and a Master of Business Administration degree from the University of Dayton in Marketing and International Business. He served six years with the USAF overseeing the development of technology used on fighter aircraft and the E-3 Surveillance aircraft, finishing his career honorably as Captain.
The city’s planning committee granted planning permission for the Rogers Stirk Harbour + Partners masterplan on the 26-acre site following two years of public consultation. The site is around Cambridge’s Station Road area and the masterplan includes over 570,000 sq ft of offices; 331 residential units; student accommodation for 1,250 Anglia Ruskin University students; a 120-bed hotel; a new station square, transport interchange and station concourse; 56,000 sq ft of retail; and community facilities. Sven Topel, group development and investment director of Ashwell, said: ‘With the Masterplan for this strategic site now approved the city of Cambridge is a significant step closer to getting the world-class gateway it deserves.’ David Tannahill, Network Rail commercial development manager, said: ‘Over the past two years we have worked closely with Ashwell to create a scheme that will deliver significant improvements to Cambridge station, benefiting the local community and passengers.‘These improvements are the direct result of consultation with our rail industry partners. We can now move forward with this scheme with Ashwell.’ Ashwell will now draw up detailed designs for a series of detailed planning applications.
To access this article REGISTER NOWWould you like print copies, app and digital replica access too? SUBSCRIBE for as little as £5 per week. Would you like to read more?Register for free to finish this article.Sign up now for the following benefits:Four FREE articles of your choice per monthBreaking news, comment and analysis from industry experts as it happensChoose from our portfolio of email newsletters
Subscribe Get instant access to must-read content today!To access hundreds of features, subscribe today! At a time when the world is forced to go digital more than ever before just to stay connected, discover the in-depth content our subscribers receive every month by subscribing to gasworld.Don’t just stay connected, stay at the forefront – join gasworld and become a subscriber to access all of our must-read content online from just $270.
RH Petrogas Limited has successfully completed testing of the Koi-2 appraisal well in Indonesia.The Koi-2 well is located in shallow water depth of 32 meters within the Salawati Kepala Burung PSC (“Island PSC”), Indonesia. The Group conducted log analysis and three drill stem tests after the well reached its total vertical depth of 1,428 meters on 30 December 2013. Post drill evaluation confirms that the Koi structure holds estimated recoverable resources of 4 MMBO (million barrels of oil) net to the Group.The joint venture partners of Island PSC have agreed to conduct a Preliminary Front End Engineering Design (“pre-FEED”) study to evaluate the development design and concept for the field.In addition, preparatory works will soon commence on the Plan of Field Development for submission to the authorities, which will incorporate the results of the preFEED study.Francis Chang, Chief Executive Officer of RH Petrogas said, “We are extremely excited about the successful appraisal of the Koi-2 well. This opens up several analogous opportunities in the offshore area of the Island PSC. We are delighted to begin the pre-FEED study and look forward to bringing the project into successful production.”The Group has an aggregate 33.21% working interest in the Island PSC through its wholly owned subsidiaries Petrogas (Island) Ltd. and RHP Salawati Basin B.V. Its partners, PT Pertamina Hulu Energi Salawati (“Pertamina”), holds 50% participating interest of Island PSC and PetroChina International Kepala Burung Ltd. (“PetroChina”) holds the balance 16.79%.The Island PSC is operated by JOB Pertamina-PetroChina Salawati, which is a joint operating body formed between Pertamina and PetroChina. The consortium, as contractor of Indonesian government operating under the supervision of SKK Migas (Satuan Kerja Khusus Minyak dan Gas), has actively explored and produced oil and gas in the working area. [mappress]Press Release, February 21, 2014
Australian shipowner MMA Offshore has informed that its newbuild offshore vessels, the MMA Prestige and MMA Pinnacle, have been delivered and have begun their first contracts.The Australian offshore vessel owner said on social media on Wednesday that both vessels have been configured for saturation diving operations, with the modifications and mobilizations completed in Singapore and Batam and with the integration engineering solutions provided in-house. The company has not disclosed the clients nor has it released any details regarding the financial aspects of the contract.The MMA Pinnacle hull was launched on April 23, 2016, while the hull of the MMA Prestige was officially launched on November 16, 2015, both from the Batam shipyard in Indonesia.The newbuild ROV support and light construction sister vessels have been, according to specs, designed with ultra-deep water lift capabilities with an AHC subsea crane capable of lifting 100 tonnes from deck to seabed 2,000 meters below.The DP2 vessels are powered by a 10,000 kW diesel electric system consisted of four separate 2,500 kW generators. Specifications state that it can handle as much as 10 tons per square meter of deck strength for demanding payloads. Both vessels can accommodate 100 people and provide 500 kVA of power for the ROV.The vessels’ AIS data show the MMA Pinnacle anchored at the port of Mumbai, while the MMA Prestige is shown as sailing past the west coast of Borneo.Offshore Energy Today staff
A code of conduct for third-party funders of litigation has cleared its final hurdle and will be published later this month, the Gazette can report. The voluntary code, drafted by a working party set up by the Civil Justice Council as a means of providing a badge of respectability to genuine litigation funders, received the green light last week after the CJC’s main board said it was ‘content’ for the code to be published. Publication will represent the culmination of several years’ work in seeking to achieve a set of rules that can be agreed upon by funders, and which also address concerns raised by Lord Justice Jackson in his final report on civil justice. In particular, the CJC said that provisions to ensure that funders have enough money to invest in cases have been bolstered in the final version. The code will also contain a ‘QC clause’ to ensure that where there is disagreement between, for example, a claimant and funder over whether to pull out of the litigation, a senior barrister will be drafted in resolve the issue. It is understood that the final version of the code has met with widespread approval by third-party funders, with the main funders expected to sign up and become members of a new Association of Litigation Funders created by the code. Organisations acting as brokers to the third-party funding industry but are not funders themselves will be able to become associate members. The working group that drafted the code was chaired by Irwin Mitchell senior partner Michael Napier, supported by a committee including Rocco Pirozzolo, legal expenses underwriting manager at QBE; Leslie Perrin, chair of funder Calunius Capital; and Susan Dunn, head of litigation funding at Harbour Litigation Funding. Pirozzolo said the development would prove ‘an important milestone’ for the funding market. ‘Funders will look forward to the association and the code forming the basis for the market to grow. If solicitors or their clients were not persuaded by the legitimacy of funding as an option to finance a case, then any such doubts should now be dispelled.’ The final code will be launched on 23 November. A full analysis of its provisions will appear in the December issue of Gazette sister publication Litigation Funding magazine.